An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice
- 1Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University, Yongin, Republic of Korea.
- 0Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University, Yongin, Republic of Korea.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers developed an RNA aptamer targeting the PELPK sequence in carcinoembryonic antigen (CEA). This aptamer inhibits colon cancer metastasis and promotes cell death, offering potential for cancer diagnosis and therapy.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- Carcinoembryonic antigen (CEA) is overexpressed in many cancers, promoting metastasis.
- A specific amino acid sequence (PELPK) in CEA is crucial for colon cancer liver metastasis.
- Targeting CEA offers potential for cancer diagnosis and therapy.
Purpose Of The Study
- To identify ligands for the CEA PELPK domain for diagnostic and therapeutic applications.
- To develop an RNA aptamer targeting the metastasis-promoting domain of CEA.
Main Methods
- Systematic evolution of ligands by exponential enrichment (SELEX) was used to screen for RNA aptamers.
- Aptamer specificity and affinity were confirmed using mobility shift, uptake, and surface plasmon resonance assays.
- In vitro and in vivo studies assessed the aptamer's effects on cancer cell metastasis and colon cancer models in mice.
Main Results
- An RNA aptamer with high affinity and specificity for the CEA PELPK sequence was identified.
- The aptamer inhibited CEA-positive cancer cell aggregation, migration, and invasion.
- The aptamer induced anoikis in colon cancer cells and prevented liver metastasis in mice.
Conclusions
- The developed RNA aptamer targets the CEA PELPK sequence, inhibiting cancer cell migration and liver metastasis.
- The aptamer disrupts interactions with heterogeneous nuclear ribonucleoprotein M4 and death receptor 5.
- This aptamer shows promise for CEA-positive tumor identification and as an anti-cancer therapeutic agent.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.